

CURRICULUM VITAE

Dr. Jose Manuel Navero Rodriguez



1. ACADEMIC DETAILS

- Degree in Medicine and General Surgery at U.A.B.-U.D. Valle de Hebrón (1993-99).
- Specialist MIR number 409.
- Specialist in Ophthalmology. MIR Training at Hospital de Terrassa (2001-2005).
- Master in refractive surgery, 2005.
- IOBA Course in Glaucoma 2002.
- Course in Practical Clinical Optometry, 2000.
- ICR Placement in Refractive and Glaucoma Departments.
- Several theoretical-practical postgraduate courses (2000-2017) in Cornea, Glaucoma, Refractive Surgery
- vitreo-retinal surgery etc,...
- Several congresses on ophthalmology at a national and international level.
- Diploma in implanting MIGS: XEN and Cypass devices

2. WORK EXPERIENCE

- Ophthalmological Emergencies at the ICO Group 2002 – 2005
- Medical Collaborator Clínica Dexeus 2002 – 2004
- Medical Collaborator Policlínica de Terrasa 2004.
- Associate Doctor at ICR from 2004 at the Glaucoma Department and the Cataract Department.
- Associate Doctor at Hospital Sant Jaume de Calella since 2005

3. PUBLICATIONS

- **European Ophthalmology Society 2003:**
Poster: *Iris tumor with anterior chamber angle satellite lesions*
- **Spanish Ophthalmology Society 2003:**
Clinical Trial: *Técnica combinada de triamcinolona intravítrea + catarata*

en pacientes con edema macular diabético.

Video: Inyección de triamcinolona intravítrea como monoterapia o en combinación a otros procedimientos quirúrgicos.

- **Spanish Ophthalmology Society 2004:**

Clinical Trial: Trombosis venosa bilateral en paciente joven con enfermedad de Crohn.

- **ARVO 2008:**

Posters:

- *Glaucoma progresión detection: Comparison of Expert Visual Field Evaluation and GPA.*

- *Reproducibility and Relation with corneal Properties of intraocular pressure measurements with ocular response analyzer and Glaucoma Tonometry.*

- *Detection of Progression with HRT Tomographic Change Analysis.*

- **Carried out ophthalmological dissections** on the ALCON Website:

www.foto-web.com

- **Catalan Society of Ophthalmology 2012;2013:**

Posters:

- *Maculopatía hipotonía asociada a implante Cypass*

- *Glaucoma secundario a SICED tipo cogan reese*

- **Revista Oftalmología Practica:** Publication of retina photos.

- **Clinical Cases in Glaucoma Magazine:** Cuando el glaucoma no va solo

- **Article in the European Journal of Ophthalmology:**

"Glaucoma progression detection: agreement, sensitivity, and specificity of expert visual field evaluation, event analysis, and trend analysis"

- **Capítulo: Nuevos procedimientos en desarrollo.**

Libro: Cirugía de glaucoma paso a paso

- **Capítulo: Suturas liberables en Trabeculectomía.**
Libro Digital: Actualización en Cirugía de glaucoma
- **Capítulo: Via Supracoroidea. Dispositivo Cypass.**
Libro SEO: Cirugía Microincisional del Glaucoma
- **World Glaucoma Association WGA-2017:**
Poster: - *CyPass micro-stent: 3 Year postoperative results*

4. ORAL PRESENTATIONS

RAG 2002

“ Tratamiento quirúrgico del glaucoma por recesión angular ”

Spanish Ophthalmology Society 2003:

“ Estudio del OCT vs RTA en el edema macular diabético ”

“ Estudio de la triamcinolona intravitrea y presión ocular tras 6 meses ”

“ Triamcinolona intravitrea para el tratamiento del edema macular diabético difuso ”

Spanish Ophthalmology Society 2004:

“ Cirugía simultánea de triamcinolona intravitrea y catarata en pacientes con edema macular diabético difuso. ”

“ Nuevo modelo de tratamiento para el edema macular diabético difuso o multifocal severo. Un año de seguimiento. ”

Talk for residents 2003:

“ Lagrimas Artificiales”

38th Congress of the Catalan Ophthalmology Society 2007:

“Combinaciones Fijas. Que aportan?”

III Congress of the Iberoamerican Glaucoma Society 2008:

“ El paciente, debería ser tratado con iridoplastia, después de la iridotomía”

XIII Congress of the Catalan Geriatrics and Gerontology Society 2012:

“ Glaucoma en Geriatria”

Doctorate Course Sant Pau 2013:

Casos clínicos en glaucoma

Course in Advances in Multifocal Intraocular Lenses 2013 ICR

44 Congress of the Catalan Ophthalmology Society 2013:

“ Nuevos implantes en la cirugía de glaucoma: me decido y los utilizo”

Course in Advances in Glaucoma surgery (Residentes Hospital Valle Hebron)

“ Experiencia con CYPASS / Resultados a 3 años”

V Congress SIBAG 2015:

“ Modulación Postoperatoria: Ologen, Antimetabolitos, AntiVEGF”

Course in Advances in Glaucoma in the Balearic Islands 2015

“¿Puedo hacer mas segura mi trabeculectomia? Suturas liberables, Express, Ologen”

IX Controversies in Ophthalmology 2016 Bellvitge

“Trabeculectomia”

SEG 2016

“¿Cómo actuar frente al glaucoma maligno? Todo y ya o mejor paso a paso”

Latest advances in microinvasive Glaucoma surgery 2017:

“Experiencia clínica con Cypass”

Experience with OLOGEN (Tenerife and Las Palmas 2017)

5. CLINICAL TRIALS

Main researcher

GANFORT (ALLERGAN) Trial: Multicenter, Double-Masked, Randomized, Parallel Study of the safety and efficacy of Bimatoprost 0,03%/Timolol 0,5% preservative-free Ophthalmic Solution Compared with Ganfort. Once daily for 12 weeks in patients with glaucoma or ocular hypertension.

Main Co-Researcher

- Phase 3 study of XXX in adult patients with open-angle glaucoma or ocular hypertension. To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 2 dose strengths of XXX in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) after initial and repeated administrations. Allergan. 2015 – on going. o ignored
- Ensayo CYPASS (Transcend)
- A multicenter registry study to capture data with respecto to XXX clinical experience. Promotor: Trascend medical inc. 2011-2012

Sub-researcher

- A clinical safety and efficacy comparison of XXX vehicle following cataract surgery in diabetic retinopathy patients. Promotor: Alcon. 2009-2011
- Visual outcomes after bilateral surgical cataract phacoemulsification: XXX IOL implantation compared to monofocal IOL implantation. Promotor Alcon. 2011-2012
- A multicenter, randomized, controlled study of the safety and effectiveness of XXX multifocal IOL in comparison to YYY monofocal IOL in subjects with age-related macular degeneration and cataract. Promotor: Alcon. 2013-2014
- Randomized, double-masked, vehicle controlled, clinical evaluation to assess the safety and efficacy of XXX ophthalmic suspension, for improvement in clinical outcomes among diabetic subjects following cataract surgery. Promotor: Alcon. 2013-2014
- Clinical study of the XXX lens. Promotor: Alcon. 2013-2016

- Efficacy and Safety assessment of T3245 unpreserved eye drops versus Xalatan in ocular hypertensive or glaucomatous patients.
- Safety and efficacy assessment of XXX in comparison with YYY and ZZZ, in patients with primary open angle glaucoma or ocular hypertension, stabilized by YYY with ocular surface intolerance. Théa. 2014-2016. o ignored
- Evaluación del efecto de la XXX y del compuesto de YYY en la función visual de pacientes con glaucoma. Estudio piloto. ICR. 2016 – on going.
- Evaluación de la eficacia y seguridad del colirio de combinación fija de XXX y YYY al 0,5% sin conservantes frente a ZZZ en pacientes con hipertensión ocular o glaucoma. Estudio de fase III, internacional, multicéntrico, aleatorizado, enmascarado para el investigador. Théa. 2015 - 2016.
- Fast Assessment of ocular Surface Trouble. Théa. 2016 – on going.
- A prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of XXX ophthalmic solution compared to YYY (ZZZ/AAA) ophthalmic solution in subjects with elevated intraocular pressure. Promotor: INC Research. 2017
- The efficacy and safety of XXX in patients with open-angle glaucoma or ocular hypertension. Promotor Allergan. 2016-2018
- Ensayo clínico fase III, aleatorizado, con dos grupos paralelos, enmascarado para el evaluador y abierto sobre la comparación de la eficacia y la tolerabilidad de una nueva formulación sin conservantes de la combinación fija de XXX y YYY frente a ZZZ en pacientes con glaucoma primario de ángulo abierto o hipertensión ocular. Promotor: Omnivisión GmbH. 2013-2014
- Comparación de XXX vs YYY en el tratamiento del glaucoma de ángulo abierto: un estudio clínico abierto, randomizado. Promotor: Omnivision GmbH. 2012-2013
- Ensayo de determinación de dosis con XXX para evaluar la tolerabilidad y el efecto sobre la presión intraocular en pacientes con hipertensión ocular o glaucoma de ángulo abierto. Promotor Sylentis SAU. 2012-2013
- A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free dose combination of XXX and YYY eye drops to those of ZZZ and AAA eye drops given concomitantly in patients with open-angle glaucoma or ocular hypertension. Promotor: Santen Inc. 2011-2012
- A multicenter, double-masked, randomized, parallel study of the safety and efficacy of XXX/YYY preservative-free ophthalmic solution compared

with ZZZ (XXX/YYY ophthalmic solution). Once daily for 12 weeks in patients with glaucoma or ocular hypertension. Promotor: Allergan. 2011

- Efficacy and safety assessment of XXX unpreserved eyedrops vs YYY in ocular hypertensive or glaucomatous patients. Promotor: THEA. 2010
- A phase III, randomized, active comparator-controlled, twelve-week, double-masked clinical trial to compare the efficacy and safety of preservative-free of XXX and preservative-free YYY in glaucomatous and ocular hypertensive patients. Promotor: MSD. 2010